Navigation Links
Breast MRI Scan Could Determine Need for Radiation Therapy
Date:9/21/2008

SEATTLE, Sept. 21 /PRNewswire/ -- For women whose breast cancer has spread to their lymph nodes, a magnetic resonance imaging (MRI) scan could replace exploratory surgery as the method for determining whether those women need radiation therapy to treat their disease, according to a study to be presented during the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) which opens today in Boston.

In a retrospective study of 167 patients who underwent radiation therapy for invasive breast cancer after surgical staging of their tumors, physician researchers at the Seattle Cancer Care Alliance and University of Washington Medical Center found that the tumors' physiological information shown on MRI scans correlated with surgically based findings of cancer having spread to lymph nodes. This suggests that breast MRI could help determine if women scheduled to undergo surgery will later need radiation therapy and how much.

The findings are significant because the standard of care for women with breast cancer has evolved during the past five years. In the past, decisions regarding radiation therapy were made after surgery and before chemotherapy, according to lead author Christopher Loiselle, M.D., a resident in the Department of Radiation Oncology at UW Medical Center. Today, increasing numbers of women may be treated with chemotherapy before surgery.

"When you give chemotherapy first, and then perform the surgery to remove the cancer and sample the lymph nodes, you reduce your ability to know whether there was cancer in the axillary (underarm) lymph nodes before the patient was treated with chemotherapy," Loiselle said. "This raises the question: is there another way to stage those lymph nodes? Our study showed that tumor characteristics as seen on an MRI scan may be the answer."

The ultimate benefit is that some women can be spared radiation therapy, especially those with smaller tumors and tumors that have
'/>"/>

SOURCE Seattle Cancer Care Alliance
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BETHESDA, Md. , Sept. 16, 2014 ... a biotechnology company developing DCVax® personalized immune therapies for ... the first product to receive formal designation as a ... to Medicines Scheme" (EAMS) launched in the UK in ... a 2-step process for early access approval under the ...
(Date:9/16/2014)... Sept. 16, 2014 Imprimis Pharmaceuticals, Inc. (Nasdaq: ... to delivering high quality and novel medicines to physicians ... Executive Officer Mark Baum will be a ... Select Conference in New York City.  Mr. Baum will ... Dropless™ campaign in ophthalmology. The presentation is scheduled for ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Henry Schein To Present At The Leerink Partners Services Roundtable 2
(Date:9/16/2014)... (PRWEB) September 16, 2014 Cloud ... Live Streaming (HLS) & UStream API’S to serve m3u8 ... wonderful feature for broadcasting live video events with hundreds ... apps. , The App Builder is known for making ... android, iOS, BlackBerry and Windows 8 and already over ...
(Date:9/16/2014)... Wholelifeinsurancecompanies.org has released a new ... with a bad heart condition. , Clients who have ... insurance if they compare quotes. Most agencies will insure ... on the actual and past medical condition. , ... heart attacks in the past, his or her chances ...
(Date:9/16/2014)... An experimental positron emission tomography (PET) tracer is effective ... still alive, according to a case study conducted at ... at Molecular Neuroimaging (MNI) LLC in New Haven, and ... . , Specifically, the study results suggest that an ... to latch onto a protein called tau that accumulates ...
(Date:9/16/2014)... predict a man,s risk of getting prostate cancer after ... analysis of the cancer,s genetic biomarkers, reported in ... and Biomedical Innovation,s Dr Jyotsna Batra and Distinguished Professor ... large consortia of research hubs around the world, said ... in 80,000 men. , "It,s the largest analysis of ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 An experimental ... concussion-related brain disease while a person is still alive, ... School of Medicine at Mount Sinai, and at Molecular ... 16 in the journal Translational Psychiatry. , Specifically, the ... [18 F]-T807, which is designed to latch onto a ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance for Clients Who Have a Bad Heart Condition! 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 3Health News:New gene research helps pinpoint prostate cancer risk 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4
... province said the SARS virus could be stopped and could ... health department, said the average daily new cases had dropped ... He gave this assurance as he was treating three foreigners, ... were infected.// ,He said the number of cases of ...
... 2003 Annual Meeting of the American Association for Cancer Research, ... means of cancer prognosis than measuring body mass index and ... the measures for detecting breast cancer are perfect, says lead ... ,But, he says that levels of leptin which signals ...
... St Mary's Hospital, Manchester, UK, has shown that family history of ... breast cancer. A survey of a group of 99 women under ... third of them had a strong history of either breast or ... cancer, 44 per cent were found to carry// mutations in the ...
... Kansas have now studied a new electrical device,that ... victims of Parkinson's disease.,This new treatment involves implanting ... of life for Parkinson's patients. This,electrical device helps ... the,signals that otherwise cause disabling tremor. The researchers ...
... long time now a lot of health experts that to ... has been advised we should,drink at least eight 8-ounce glasses ... Researchers from Center for Human Nutrition at the,University of Nebraska ... keep ourselves hydrated.// A group of 27 male volunteers were ...
... the A & A Pain Institute in St Louis, Missouri(A ... of pain), have,found that an anticonvulsant drug levetiracetam brings dramatic ... seven patients between 39 and 67 who had,severe nerve pain ... on,the nerve, analgesic drugs were not effective in relieving the ...
Cached Medicine News:
... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
... The LightCycler 2.0 System is the ... Applied Science. This new instrument offers six ... 530, 560, 610, 640, 670, and 710nm. ... cooling by air and working with glass ...
Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...
Medicine Products: